Author: claimsbot

1. An elongate medical device for penetrating tissue, comprising:
an elongate shaft having a proximal segment and a reduced diameter distal segment, the distal segment unitarily formed with the proximal segment;
a coil positioned around the distal segment;
a tip member securing a distal end of the coil to the distal segment; and
a distal portion of the distal segment extending distal of the distal end of the coil and extending distal of a distalmost end of the tip member;
wherein the distal portion of the distal segment defines a probe adapted and configured to pierce tissue.
2. The elongate medical device of claim 1, wherein the probe defines a distalmost end of the elongate medical device.
3. The elongate medical device of claim 1, wherein the probe is exposed from all other components of the elongate medical device.
4. The elongate medical device of claim 1, wherein the elongate shaft includes a tapered segment between the proximal segment and the distal segment.
5. The elongate medical device of claim 4, wherein a proximal end of the coil is secured to the tapered segment of the elongate shaft.
6. The elongate medical device of claim 5, wherein the proximal segment has a constant diameter.
7. The elongate medical device of claim 6, wherein the distal segment has a constant diameter.
8. The elongate medical device of claim 1, wherein the probe extends distally beyond all other components of the elongate medical device by a distance that is greater than about 0.003 inches.
9. The elongate medical device of claim 8, wherein the probe extends distally beyond all other components of the elongate medical device by a distance that is less than about 0.012 inches.
10. The elongate medical device of claim 1, wherein the elongate shaft comprises a bend disposed between the proximal segment and the distal portion of the distal segment such that the distal portion of the distal segment extends at an angle to the proximal segment, the angle being greater than about 90 degrees and less than about 180 degrees.
11. The elongate medical device of claim 10, wherein the angle is greater than about 120 degrees and less than about 150 degrees.
12. An elongate medical device for penetrating tissue, comprising:
an elongate shaft having a proximal segment and a reduced diameter distal segment, the distal segment unitarily formed with the proximal segment;
a tubular component positioned around the distal segment of the elongate shaft; and
a distal portion of the distal segment extending distal of a distal end of the tubular component and forming a probe adapted and configured to pierce tissue;
the probe being exposed from all other components of the elongate medical device and defining a distalmost end of the elongate medical device.
13. The elongate medical device of claim 12, wherein the elongate shaft includes a tapered segment between the proximal segment and the distal segment.
14. The elongate medical device of claim 13, wherein a proximal end of the tubular component is secured to the tapered segment of the elongate shaft.
15. The elongate medical device of claim 14, wherein the proximal segment has a constant diameter.
16. The elongate medical device of claim 15, wherein the distal segment has a constant diameter.
17. The elongate medical device of claim 12, wherein the probe extends distally beyond all other components of the elongate medical device by a distance that is greater than about 0.003 inches.
18. The elongate medical device of claim 17, wherein the probe extends distally beyond all other components of the elongate medical device by a distance that is less than about 0.012 inches.
19. The elongate medical device of claim 12, wherein the elongate shaft comprises a bend disposed between the proximal segment and the distal portion of the distal segment such that the distal portion of the distal segment extends at an angle to the proximal segment, the angle being greater than about 90 degrees and less than about 180 degrees.
20. The elongate medical device of claim 19, wherein the angle is greater than about 120 degrees and less than about 150 degrees.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A hydraulic transfer film comprising a laminated body including on a water-soluble film an extension control resin layer, and a luster ink layer containing a luster pigment and a binder resin, wherein
the hydraulic transfer film has an irregularity shape on a surface of the laminated body on a side opposite to the water-soluble film, and
a resin that forms the extension control resin layer contains a resin A having a glass transition temperature of 80\xb0 C. or higher.
2. The hydraulic transfer film according to claim 1, comprising the extension control resin layer and the luster ink layer in this order on the water-soluble film.
3. The hydraulic transfer film according to claim 1, comprising the luster ink layer and the extension control resin layer in this order on the water-soluble film.
4. The hydraulic transfer film according to claim 1, wherein the glass transition temperature of the resin A is 80 to 145\xb0 C.
5. The hydraulic transfer film according to claim 1, wherein the resin A is a water-insoluble resin.
6. The hydraulic transfer film according to claim 1, wherein the resin A is at least one selected from an acrylic resin, an acrylic polyol resin, a nitrocellulose resin and a vinyl chloride-vinyl acetate copolymer resin.
7. The hydraulic transfer film according to claim 1, wherein a content of the resin A in the resin that forms the extension control resin layer is 50% by mass or more.
8. The hydraulic transfer film according to claim 1, wherein the binder resin that forms the luster ink layer is a mixture of a nitrocellulose resin and an alkyd resin.
9. The hydraulic transfer film according to claim 3, wherein the extension control layer has a multilayer structure of two or more layers.
10. The hydraulic transfer film according to claim 9, wherein a resin that forms an extension control resin layer located at the outermost surface among the extension control layers in the multilayer structure includes an alkyd resin and a nitrocellulose resin as the resin A.
11. The hydraulic transfer film according to claim 9, wherein among the extension control layers in the multilayer structure, extension control resin layers other than the extension control layer located at the outermost surface contain an acrylic polyol resin as the resin A.
12. The hydraulic transfer film according to claim 2, further comprising a second extension control resin layer, which contains the resin A, on the luster ink layer on a side opposite to the extension control resin layer.
13. The hydraulic transfer film according to claim 12, wherein the second extension control resin layer contains an alkyd resin and a nitrocellulose resin as the resin A.
14. A method for producing a hydraulic transfer film, the method comprising the following steps (1) and (2) in order:
step (1): a step of laminating on a water-soluble film an extension control resin layer formed of a resin composition containing a resin A having a glass transition temperature of 80\xb0 C. or higher, and a luster ink layer containing a luster pigment and a binder resin; and
step (2): a step of performing embossing from a surface of the laminated body on a side opposite to the water-soluble film.
15. A method for producing a decorative molded article, the method comprising the following steps (a) to (c) in order:
step (a): an activator applying step of applying, before or after floating the hydraulic transfer film according to claim 1 on a water surface with the water-soluble film facing the water surface, an activator composition to a surface of the hydraulic transfer film on a side opposite to the water-soluble film;
step (b): a step of pressing a transfer object against the activator composition-applied surface of the hydraulic transfer film subjected to the step (a) and floated on the water surface, and adhering the hydraulic transfer film to a transfer surface of the transfer object by means of a hydraulic pressure; and
step (c): a film removing step of removing the water-soluble film adhered to the transfer surface of the transfer object.

1. A method of aligning antennas of an intra-oral and extra-oral electronic wireless device, comprising the steps of:
recording three-dimensional anatomical data of at least a portion of an oral cavity of a subject utilizing an imaging device;
recording three-dimensional anatomical data of at least a portion of an external ear of the subject utilizing the imaging device;
determining a spatial relationship between a landmark in the oral cavity and a landmark in or near the external ear;
modeling an intra-oral antenna based upon the recorded anatomical data of the oral cavity; and
modeling an extra-oral antenna based upon the recorded anatomical data of the external ear, wherein the intra-oral and extra-oral antennas are configured and oriented relative to each other for optimal signal transmission based upon the recorded anatomical data of the oral cavity and external ear.
2. The method of claim 1, wherein the imaging device is a non-ionizing radiation system.
3. The method of claim 1, wherein the imaging device is selected from the group consisting of an X-ray imaging system, a computed tomography imaging system, a magnetic resonance imaging system, and an optical imaging system.
4. The method of claim 1, comprising the further steps of:
constructing an internal unit configured to be disposed within the oral cavity of the subject, the intra-oral antenna coupled to the internal unit; and
constructing an external unit configured to be disposed within or proximate to the ear of the subject, the extra-oral antenna coupled to the external unit.
5. The method of claim 4, wherein the intra-oral and extra-oral antennas are fixedly and spatially oriented relative to each other for optimal gain and polarization when the internal and external units are disposed within or upon the subject.
6. The method of claim 1, wherein the intra-oral antenna has a first angular orientation, and the extra-oral antenna has a second angular orientation relative to the first angular orientation, wherein the signal transmission is optimized when the intra-oral and extra-oral antennas are orientated in the first and second angular orientations, respectively.
7. The method of claim 1, wherein the imaging device is an ionizing radiation system.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A compound of formula
or a pharmaceutically acceptable salt thereof or a prodrug thereof wherein
R1 to R10 are each independently selected from hydrogen or a straight or branched alkyl of from 1 to 6 carbons, benzyl, or phenyl;
m is an integer of from 0 to 3;
n is an integer of from 1 to 2;
o is an integer of from 0 to 3;
p is an integer of from 1 to 2;
q is an integer of from 0 to 2;
r is an integer of from 1 to 2;
s is an integer of from 1 to 3;
t is an integer of from 0 to 2; and
u is an integer of from 0 to 1.
2. A compound according to claim 1 of Formula I.
3. A compound according to claim 1 of Formula I wherein
R1 to R10 is hydrogen;
m is of from 0 to 3; and
n is 1 or 2.
4. A compound according to claim 1 selected from:
(\xb1)-2-Aza-spiro3.5nonane-1-carboxylic acid hydrochloride;
(\xb1)-2-Aza-spiro4.5decane-4-carboxylic acid hydrochloride;
(R)-2-Aza-spiro4.5decane-4-carboxylic acid hydrochloride;
(S)-2-Aza-spiro4.5decane-4-carboxylic acid hydrochloride; and
(R)-2-Aza-spiro4.5decane-4-carboxylic acid.
5. A compound according to claim 1 of Formula II.
6. A compound according to claim 1 of Formula II wherein
R1 to R10 is hydrogen,
o is from 0 to 3; and
p is 1 to 2.
7. A compound according to claim 1 of Formula III wherein
R1 to R10 is hydrogen,
q is from 0 to 2; and
r is 1 to 2.
8. A compound according to claim 1 of Formula III wherein:
(+)-3aS-(3\u03b1,7a\u03b1)-(Octahydro-isoindol-3a-yl)-acetic acid trifluoroacetate.
9. A compound according to claim 1 and selected from:
7-Methyl-2-aza-spiro4.4nonane-4-carboxylic acid;
4\u03b1,5\u03b2(R*)7-Methyl-2-aza-spiro4.5decane-4-carboxylic acid;
4\u03b1,5\u03b1(S*)7-Methyl-2-aza-spiro4.5decane-4-carboxylic acid;
4\u03b1,5\u03b1(R*)7-Methyl-2-aza-spiro4.5decane-4-carboxylic acid;
4\u03b1,5\u03b2(S*)7-Methyl-2-aza-spiro4.5decane-4-carboxylic acid;
7,8-Dimethyl-2-aza-spiro4.4nonane-4-carboxylic acid;
7-Methyl-2-aza-spiro4.5decane-4-carboxylic acid;
7,9-Dimethyl-2-aza-spiro4.5decane-4-carboxylic acid;
Spirobicyclo3.3.1nonane-9,3\u2032-pyrrolidine-4\u2032-carboxylic acid;
Spiropyrrolidine-3,2\u2032-tricyclo3.3.1.13,7decane-4-carboxylic acid;
3-Amino-6-methyl-spiro3.5nonane-1-carboxylic acid;
3-Amino-6,8-dimethyl-spiro3.5nonane-1-carboxylic acid;
4-Amino-7-methyl-spiro4.5decane-1-carboxylic acid;
4-Amino-7,9-dimethyl-spiro4.5decane-1-carboxylic acid;
3-Amino-6-methyl-spiro3.4octane-1-carboxylic acid;
3-Amino-6,7-dimethyl-spiro3.4octane-1-carboxylic acid;
4-Amino-7-methyl-spiro4.4nonane-1-carboxylic acid; and
4-Amino-7,8-dimethyl-spiro4.4nonane-1-carboxylic acid.
10. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.
11. A method for treating epilepsy comprising administering a therapeutically effective amount of a compound according to claim 1 to a mammal in need of said treatment.
12. A method for treating faintness attacks, hypokinesia, and cranial disorders comprising administering a therapeutically effective amount of a compound according to claim 1 to a mammal in need of said treatment.
13. A method for treating neurodegenerative disorders comprising administering a therapeutically effective amount of a compound according to claim 1 to a mammal in need of said treatment.
14. A method for treating depression comprising administering a therapeutically effective amount of a compound according to claim 1 to a mammal in need of said treatment.
15. A method for treating anxiety comprising administering a therapeutically effective amount of a compound according to claim 1 to a mammal in need of said treatment.
16. A method for treating panic comprising administering a therapeutically effective amount of a compound according to claim 1 to a mammal in need of said treatment.
17. A method for treating pain comprising administering a therapeutically effective amount of a compound according to claim 1 to a mammal in need of said treatment.
18. A method for treating neuropathological disorders comprising administering a therapeutically effective amount of a compound according to claim 1 to a mammal in need of said treatment.
19. A compound selected from:
2-Benzyl-2-aza-spiro4.5decane-4,4-dicarboxylic acid dimethyl ester hydrochloride;
2-Aza-spiro4.5decane-4,4-dicarboxylic acid dimethyl ester hydrochloride;
1-Benzyloxymethyl-2-aza-spiro3.5nonane-2-carboxylic acid tert-butyl ester;
1-Hydroxymethyl-2-aza-spiro3.5nonane-2-carboxylic acid tert-butyl ester;
2-Aza-spiro3.5nonane-1,2-dicarboxylic acid 2-tert-butyl ester;
3aS-(3\u03b17a\u03b1)-7a-tert-Butoxycarbonylmethyl-1-oxo-octahydro-isoindole-2-carboxylic acid tert-butyl ester; and
3aS-(\u03b17a\u03b1)-3a-tert-Butoxycarbonylmethyl-octahydro-isoindole-2-carboxylic acid tert-butyl ester.